Ceryvyn Therapeutics-ADRCYVNY
13F holders, Q2 2025 (June 30)8holders −1
1new positions
2sold out
1famous investor
$0.05avg. 13F price*
At the end of Q2 2025, 8 institutions reported holding Ceryvyn Therapeutics-ADR (CYVNY) in their 13F filings, down 1 from Q1 2025. 1 opened new positions and 2 sold out. The largest holders were HSBC Holdings PLC ($356K), UBS Group AG ($27K) and Millennium Management ($8K). One famous investor held it Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Ceryvyn Therapeutics-ADR
- Filed as
- OPTHEA LTD (Q2 2025)
- CUSIP
- 68386J208
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $0 |
| Exits | 2 | $113K |
All 13F filers, Q1 2025 → Q2 2025: 5,954 shares bought and 52,323 shares sold, net −46,369 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| HSBC Holdings PLC | 0.00% | No change | 105,939 | $356K |
| UBS Group AG | 0.00% | No change | 7,773 | $27K |
| Millennium Management | 0.00% | No change | 48,329 | $8K |
| Morgan Stanley | 0.00% | No change | 765 | $3K |
| Raymond James Financial Inc. | 0.00% | New | 5,954 | $0 |
| Baker Bros. Advisors LP | 0.00% | No change | 2,087,320 | $0 |
| EP Wealth Advisors, LLC | 0.00% | No change | 10,000 | $0 |
| Regal Partners Ltd | 0.00% | No change | 5,193,688 | $0 |
"% of holder's portfolio" is CYVNY's weight in each manager's 13F, not the share of Ceryvyn Therapeutics-ADR the manager owns.